164 related articles for article (PubMed ID: 12933925)
21. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive.
Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA
Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118
[TBL] [Abstract][Full Text] [Related]
24. A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta.
Kob M; Harvey J; Schautzer F; Kascha S; Bibl D; Egg R; Reindl M; Berger T; Deisenhammer F
Mult Scler; 2003 Feb; 9(1):32-5. PubMed ID: 12617265
[TBL] [Abstract][Full Text] [Related]
25. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
26. Neutralising antibodies against interferon beta in multiple sclerosis.
Antonelli G
Lancet; 2004 Jan; 363(9403):168; author reply 168-9. PubMed ID: 14726180
[No Abstract] [Full Text] [Related]
27. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
29. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
[TBL] [Abstract][Full Text] [Related]
30. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
[TBL] [Abstract][Full Text] [Related]
31. Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy.
Hesse D; Sørensen PS
Eur J Neurol; 2007 Aug; 14(8):850-9. PubMed ID: 17662004
[TBL] [Abstract][Full Text] [Related]
32. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive.
Khan OA; Dhib-Jalbut SS
Neurology; 1998 Dec; 51(6):1698-702. PubMed ID: 9855525
[TBL] [Abstract][Full Text] [Related]
33. Neutralising antibodies against interferon beta in multiple sclerosis.
Giovannoni G; Deisenhammer F
Lancet; 2004 Jan; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
[No Abstract] [Full Text] [Related]
34. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
35. Development of resistance to biologic therapies with reference to IFN-β.
Farrell RA; Marta M; Gaeguta AJ; Souslova V; Giovannoni G; Creeke PI
Rheumatology (Oxford); 2012 Apr; 51(4):590-9. PubMed ID: 22258390
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group.
Neurology; 1996 Oct; 47(4):889-94. PubMed ID: 8857714
[TBL] [Abstract][Full Text] [Related]
37. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
38. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
[TBL] [Abstract][Full Text] [Related]
39. Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres.
Bellomi F; Bramanti P; Trojano M; Scagnolari C; Muto A; Sessa E; La Volpe V; Russo P; Antonelli G
J Immunoassay Immunochem; 2009; 30(1):40-50. PubMed ID: 19117201
[TBL] [Abstract][Full Text] [Related]
40. Neutralising antibodies against interferon beta in multiple sclerosis.
Mikol D
Lancet; 2004 Jan; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
